Indoco Remedies Q1 Revenue at ₹3,838 Lakhs, Up 12.5% Q-o-Q
The positive revenue growth and management's optimistic outlook suggest a potentially positive impact on the company's performance. However, the losses in subsidiaries temper the overall impact.
The announcement highlights a significant increase in revenue and EBIDTA compared to the previous quarter, and the management expresses confidence in sustaining this momentum.
* Indoco Remedies Limited announced its unaudited standalone and consolidated financial results for the quarter ended 30th June, 2025. * Revenue for Q1 FY26 stood at ₹3,838 lakhs, a 12.5% increase compared to ₹3,411 lakhs in the previous quarter. * The company's EBIDTA for the quarter was ₹148 lakhs, compared to ₹35 lakhs in the previous quarter. * Net loss of FPP Holding LLC was ₹373.03 lakhs, with a negative net worth of ₹2,806.71 lakhs. * Net loss of Warren Remedies Private Limited stood at ₹556.70 lakhs, with a negative net worth of ₹5,202.87 lakhs. * Aditi Panandikar, Managing Director, commented: "Our 12.5% revenue growth this quarter over last quarter reflects the resilience of our teams, operational excellence and robust strategy. We are confident of sustaining this momentum and making a turnaround going ahead."
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.